Topadur Pharma AG, founded in 2015 in Schlieren, is a clinical-stage biopharmaceutical company. Leveraging its proprietary DualTOP™ platform, Topadur develops dual-acting molecules that restore cGMP levels, repairing microcirculation, promoting tissue regeneration, and addressing oxygen deficiency.
Products, services, technology
Lead candidate TOP-N53 is in Phase 2a for systemic sclerosis digital ulcers with EMA and FDA orphan drug status. TOP-M119, co-developed with Oshen Holdings, targets alopecia. Programs also explore regenerative medicine, oncology, ophthalmology, diabetic ulcers, and fibrosis.
Cooperation possibilities
Led by an experienced team, Topadur advances its pipeline toward major milestones. The company actively welcomes partnering discussions to accelerate clinical progress and expand applications of its innovative therapeutic programs.
- https://www.topadur.com
- +41 44 755 44 66
- Send an email
- Dr. Reto Naef
